ArticleFrontiers in medicine2019

Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes.

Thomas Mika et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.